Design, synthesis, and biological evaluation of thiazole/thiadiazole carboxamide scaffold-based derivatives as potential c-Met kinase inhibitors for cancer treatment

References

• WHO; 2023. https://www.who.int/en/news-room/fact-sheets/detail/cancer.
   Google Scholar
• Lu X, Smaill JB, Ding K. Medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations. J Med Chem. 2020;63(19):10726–10741.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim J, Jo J, Chang JW, Sim J, Yun H. Recent advances in development of hetero-bivalent kinase inhibitors. Eur J Med Chem. 2021;216:113318.
   PubMed Web of Science ®Google Scholar
• Lu X, Smaill JB, Ding K. New promise and opportunities for allosteric kinase inhibitors. Angew Chem Int Ed Engl. 2020;59(33):13764–13776.
   PubMed Web of Science ®Google Scholar
• Liu G-H, Chen T, Zhang X, Ma X-L, Shi H-S. Small molecule inhibitors targeting the cancers. MedComm. 2022;3(4):e181.
   PubMedGoogle Scholar
• Ayala-Aguilera CC, Valero T, Lorente-Macías Á, Baillache DJ, Croke S, Unciti-Broceta A. Small molecule kinase inhibitor drugs (1995–2021): medical indication, pharmacology, and synthesis. J Med Chem. 2022;65(2):1047–1131.
   PubMed Web of Science ®Google Scholar
• Giordano S, Ponzetto C, Renzo MFD, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 1989;339(6220):155–156.
   PubMed Web of Science ®Google Scholar
• Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, Rowley JD, Blair DG, Vande Woude GF. The human met oncogene is related to the tyrosine kinase oncogenes. Nature. 1985;318(6044):385–388.
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–804.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–925.
   PubMed Web of Science ®Google Scholar
• Parikh PK, Ghate MD. Recent advances in the discovery of small molecule c-Met kinase inhibitors. Eur J Med Chem. 2018;143:1103–1138.
   PubMed Web of Science ®Google Scholar
• Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 2014;57(11):4427–4453.
   PubMed Web of Science ®Google Scholar
• Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung P-P, Pairish M, Jia L, Meng J, Funk L, Botrous I, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342–6363.
   PubMed Web of Science ®Google Scholar
• Bhutani P, Joshi G, Raja N, Bachhav N, Rajanna PK, Bhutani H, Paul AT, Kumar R. U.S. FDA approved drugs from 2015–June 2020: a perspective. J Med Chem. 2021;64(5):2339–2381.
   PubMed Web of Science ®Google Scholar
• Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, Jiao L, Cui Y, Ren Y, Fan S, et al. Discovery of (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal–epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014;57(18):7577–7589.
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646.
   PubMed Web of Science ®Google Scholar
• Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2016;11(8):1242–1245.
   PubMed Web of Science ®Google Scholar
• Frigault MM, Markovets A, Nuttall B, Kim K-M, Park SH, Gangolli EA, Mortimer PGS, Hollingsworth SJ, Hong JY, Kim K, et al. Mechanisms of acquired resistance to savolitinib, a selective MET inhibitor in MET-amplified gastric cancer. JCO Precis Oncol. 2020;4:222–232.
   Web of Science ®Google Scholar
• Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo Y-C, Li YY, Lamberti G, Nguyen T, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC. Clin Cancer Res. 2020;26(11):2615–2625.
   PubMed Web of Science ®Google Scholar
• Underiner TL, Herbertz T, Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem. 2010;10(1):7–27.
   PubMed Web of Science ®Google Scholar
• Wang Z, Shi J, Zhu X, Zhao W, Gong Y, Hao X, Hou Y, Liu Y, Ding S, Liu J, et al. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors. Bioorg Chem. 2020;105:104371.
   PubMed Web of Science ®Google Scholar
• Nan X, Jiang Y-F, Li H-J, Wang J-H, Wu Y-C. Design, synthesis and evaluation of sulfonylurea containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors. Bioorg Med Chem. 2019;27(13):2801–2812.
   PubMed Web of Science ®Google Scholar
• Collie GW, Barlind L, Bazzaz S, Börjesson U, Dale IL, Disch JS, Habeshian S, Jetson R, Khurana P, Madin A, et al. Discovery of a selective c-MET inhibitor with a novel binding mode. Bioorg Med Chem Lett. 2022;75:128948.
   PubMed Web of Science ®Google Scholar
• Wang M-S, Xu H-C, Gong Y, Qu R-Y, Zhuo L-S, Huang W. Efficient arylation of 2,7-naphthyridin-1(2H)-one with diaryliodonium salts and discovery of a new selective MET/AXL kinase inhibitor. ACS Comb Sci. 2020;22(9):457–467.
   PubMed Web of Science ®Google Scholar
• Hu H, Chen F, Dong Y, Liu Y, Gong P. Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorg Chem. 2020;101:103970.
   PubMed Web of Science ®Google Scholar
• Hu H, Chen F, Dong Y, Li M, Xu S, Qin M, Gong P. Discovery of novel c-mesenchymal–epithelia transition factor and histone deacetylase dual inhibitors. Eur J Med Chem. 2020;204:112651.
   PubMed Web of Science ®Google Scholar
• Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors. Bioorg Med Chem. 2016;24(6):1331–1345.
   PubMed Web of Science ®Google Scholar
• Liu L, Norman MH, Lee M, Xi N, Siegmund A, Boezio AA, Booker S, Choquette D, D'Angelo ND, Germain J, et al. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series. J Med Chem. 2012;55(5):1868–1897.
   PubMed Web of Science ®Google Scholar
• Nan X, Li H-J, Fang S-B, Li Q-Y, Wu Y-C. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions. Eur J Med Chem. 2020;193:112241.
   PubMed Web of Science ®Google Scholar
• Nan X, Zhang J, Li H-J, Wu R, Fang S-B, Zhang Z-Z, Wu Y-C. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu catalyzed three-component reaction. Eur J Med Chem. 2020;200:112470.
   PubMed Web of Science ®Google Scholar
• Schroeder GM, An Y, Cai Z-W, Chen X-T, Clark C, Cornelius LAM, Dai J, Gullo-Brown J, Gupta A, Henley B, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem. 2009;52(5):1251–1254.
   PubMed Web of Science ®Google Scholar
• Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, et al. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem. 2008;51(13):3688–3691.
   PubMed Web of Science ®Google Scholar
• Chen X, Shu C, Li W, Hou Q, Luo G, Yang K, Wu X. Discovery of a novel Src homology 2 domain containing protein tyrosine phosphatase 2 (SHP2) and cyclin-dependent kinase 4 (CDK4) dual inhibitor for the treatment of triple-negative breast cancer. J Med Chem. 2022;65(9):6729–6747.
   PubMed Web of Science ®Google Scholar
• Kumari S, Carmona AV, Tiwari AK, Trippier PC. Amide bond bioisosteres: strategies, synthesis, and successes. J Med Chem. 2020;63(21):12290–12358.
   PubMed Web of Science ®Google Scholar
• Majumdar P, Pati A, Patra M, Behera RK, Behera AK. Acid hydrazides, potent reagents for synthesis of oxygen, nitrogen, and/or sulfur-containing heterocyclic rings. Chem Rev. 2014;114(5):2942–2977.
   PubMed Web of Science ®Google Scholar
• Cascioferro S, Parrino B, Carbone D, Schillaci D, Giovannetti E, Cirrincione G, Diana P. Thiazoles, their benzofused systems, and thiazolidinone derivatives: versatile and promising tools to combat antibiotic resistance. J Med Chem. 2020;63(15):7923–7956.
   PubMed Web of Science ®Google Scholar
• Dawood KM, Farghaly TA. Thiadiazole inhibitors: a patent review. Expert Opin Ther Pat. 2017;27(4):477–505.
   PubMed Web of Science ®Google Scholar
• Altıntop MD, Ciftci HI, Radwan MO, Sever B, Kaplancıklı ZA, Ali TFS, Koga R, Fujita M, Otsuka M, Özdemir A. Design, synthesis, and biological evaluation of novel 1,3,4-tiadiazole derivatives as potential antitumor agents against chronic myelogenous leukemia: striking effect of nitrothiazole moiety. Molecules. 2018;23(1):59.
   Web of Science ®Google Scholar
• Janowska S, Khylyuk D, Bielawska A, Szymanowska A, Gornowicz A, Bielawski K, Noworól J, Mandziuk S, Wujec M. New 1,3,4-thiadiazole derivatives with anticancer activity. Molecules. 2022;27(6):1814.
   PubMed Web of Science ®Google Scholar
• Morigi R, Locatelli A, Leoni A, Rambaldi M. Recent patents on thiazole derivatives endowed with antitumor activity. Recent Pat Anticancer Drug Discov. 2015;10(3):280–297.
   PubMed Web of Science ®Google Scholar
• Davison EK, Sperry J. Natural products with heteroatom-rich ring systems. J Nat Prod. 2017;80(11):3060–3079.
   PubMed Web of Science ®Google Scholar
• Pomeislová A, Otmar M, Rubešová P, Benýšek J, Matoušová M, Mertlíková-Kaiserová H, Pohl R, Poštová Slavětínská L, Pomeisl K, Krečmerová M, et al. 1,2,4-Thiadiazole acyclic nucleoside phosphonates as inhibitors of cysteine dependent enzymes cathepsin K and GSK-3β. Bioorg Med Chem. 2021;32:115998.
   PubMed Web of Science ®Google Scholar
• Farghaly TA, Abbas EMH, Al-Soliemy AM, Sabour R, Shaaban MR. Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: design, synthesis, biological evaluation and molecular docking studies. Bioorg Chem. 2022;121:105684.
   PubMed Web of Science ®Google Scholar
• Orujova T, Ece A, Akalın Çiftçi G, Özdemir A, Altıntop MD. A new series of thiazole‐hydrazone hybrids for Akt‐targeted therapy of non‐small cell lung cancer. Drug Dev Res. 2023;84(2):185–199.
   PubMed Web of Science ®Google Scholar
• Ayati A, Emami S, Asadipour A, Shafiee A, Foroumadi A. Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. Eur J Med Chem. 2015;97:699–718.
   PubMed Web of Science ®Google Scholar
• Sharma PC, Bansal KK, Sharma A, Sharma D, Deep A. Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur J Med Chem. 2020;188:112016.
   PubMed Web of Science ®Google Scholar
• Elewa AM, Jayakumar J, Huang Y-W, Elsayed MH, Chang C-L, Ting L-Y, Lin W-C, Chueh C-C, Chou H-H. Biaxially extended side-chain conjugation of benzodithiophene-based polymer dots for superior photocatalytic stability under visible-light irradiation. J Environ Chem Eng. 2022;10(1):106927.
   Web of Science ®Google Scholar
• Qi B, Mi B, Zhai X, Xu Z, Zhang X, Tian Z, Gong P. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors. Bioorg Med Chem. 2013;21(17):5246–5260.
   PubMed Web of Science ®Google Scholar
• Wang L, Xu S, Liu X, Chen X, Xiong H, Hou S, Zou W, Tang Q, Zheng P, Zhu W, et al. Discovery of thinopyrimidine–triazole conjugates as c-Met targeting and apoptosis inducing agents. Bioorg Chem. 2018;77:370–380.
   PubMed Web of Science ®Google Scholar
• Claridge S, Raeppel F, Granger M-C, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R, Rahil J, et al. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg Med Chem Lett. 2008;18(9):2793–2798.
   PubMed Web of Science ®Google Scholar
• Tan L, Zhang Z, Gao D, Chan S, Luo J, Tu Z-C, Zhang Z-M, Ding K, Ren X, Lu X, et al. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. Eur J Med Chem. 2019;166:318–327.
   PubMed Web of Science ®Google Scholar
• Ogasawara D, Ichu T-A, Vartabedian VF, Benthuysen J, Jing H, Reed A, Ulanovskaya OA, Hulce JJ, Roberts A, Brown S, et al. Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo. Nat Chem Biol. 2018;14(12):1099–1108.
   PubMed Web of Science ®Google Scholar
• Howe RK, Gruner TA, Franz JE. Nitrile sulfides. Synthesis of 5-aryl-1,2,4-thiadiazole-3-carboxylates. J Org Chem. 1977;42(10):1813–1814.
   Web of Science ®Google Scholar
• Fordyce EAF, Morrison AJ, Sharp RD, Paton RM. Microwave-induced generation and reactions of nitrile sulfides: an improved method for the synthesis of isothiazoles and 1,2,4-thiadiazoles. Tetrahedron. 2010;66(35):7192–7197.
   Web of Science ®Google Scholar
• Liu M, Liang Y, Zhu Z, Wang J, Cheng X, Cheng J, Xu B, Li R, Liu X, Wang Y, et al. Discovery of novel aryl carboxamide derivatives as hypoxia-inducible factor 1α signaling inhibitors with potent activities of anticancer metastasis. J Med Chem. 2019;62(20):9299–9314.
   PubMed Web of Science ®Google Scholar
• Schäfer G, Fleischer T, Ahmetovic M, Abele S. Development of a scalable route for a key thiadiazole building block via sequential Sandmeyer bromination and room temperature Suzuki–Miyaura coupling. Org Process Res Dev. 2020;24(2):228–234.
   Web of Science ®Google Scholar
• Li Z, Chen Y, Zhou Z, Deng L, Xu Y, Hu L, Liu B, Zhang L. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents. Eur J Med Chem. 2019;164:352–365.
   PubMed Web of Science ®Google Scholar
• Günther M, Lategahn J, Juchum M, Döring E, Keul M, Engel J, Tumbrink HL, Rauh D, Laufer S. Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site. J Med Chem. 2017;60(13):5613–5637.
   PubMed Web of Science ®Google Scholar
• Haydon PG, Lee J. Uridine nucleoside derivatives, compositions and methods of use. WO2018058148-Al; 2018.
   Google Scholar
• Sybo B, Bradley P, Grubb A, Miller S, Proctor KJW, Clowes L, Lawrie MR, Sampson P, Seed AJ. 1,3,4-Thiadiazole-2-carboxylate esters: new synthetic methodology for the preparation of an elusive family of self-organizing materials. J Mater Chem. 2007;17(32):3406–3411.
   Web of Science ®Google Scholar
• Feng W, Zhang B, Zhao H, Zhang Y, Li Y, Chen Z, Liu B, Cao X. c-Met inhibitor SGX523-induced apoptosis of breast cancer cells MDA-MB-231. Chin J Clin Oncol. 2012;39(2):61–64.
   Google Scholar
• Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504–516.
   PubMed Web of Science ®Google Scholar
• Munshi N, Jeay S, Li Y, Chen C-R, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9(6):1544–1553.
   PubMed Web of Science ®Google Scholar